(Q38604854)

4 September 2017

title

Entrectinib: a potent new TRK, ROS1, and ALK inhibitor (English)

1 reference

4 September 2017

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26457764%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Elisa Giovannetti

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26457764%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Ignacio Gil-Bazo

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26457764%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

author name string

Christian Rolfo

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26457764%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Antonio Russo

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26457764%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Francesco Passiglia

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26457764%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Marco Giallombardo

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26457764%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Marc Peeters

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26457764%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Luis Raez

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26457764%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

language of work or name

English

0 references

publication date

12 October 2015

1 reference

Expert Opinion on Investigational Drugs

4 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26457764%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

volume

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26457764%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26457764%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

page(s)

1493-1500

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26457764%20AND%20SRC:MED&resulttype=core&format=json

New approaches to molecular cancer therapeutics

4 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1096344

Analysis of stage and clinical/prognostic factors for lung cancer from SEER registries: AJCC staging and collaborative stage data collection system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1096344

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1096344

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1096344

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1096344

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1096344

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1096344

The protein tyrosine kinase family of the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1096344

Oncogenic kinase signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1096344

Cell signaling by receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1096344

Receptor tyrosine kinases as targets for anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1096344

Cell signaling by receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1096344

Discovery and preclinical characterization of novel small molecule TRK and ROS1 tyrosine kinase inhibitors for the treatment of cancer and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1096344

Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: Recent Progress and Future Directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1096344

Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1096344

Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1096344

Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1096344

ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1096344

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1096344

The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1096344

Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1096344

Molecular pathways: ROS1 fusion proteins in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1096344

ROS1 rearrangements define a unique molecular class of lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1096344

ROS1 as a 'druggable' receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1096344

Trk receptor expression and inhibition in neuroblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1096344

Structural and functional properties of the TRK family of neurotrophin receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1096344

Trk receptor tyrosine kinases: a bridge between cancer and neural development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1096344

Physiology of the neurotrophins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1096344

Neurotrophin signal transduction in the nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1096344

Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1096344

TrkA overexpression enhances growth and metastasis of breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1096344

Rearrangements of NTRK1 gene in papillary thyroid carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1096344

A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1096344

The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1096344

Role and relevance of TrkB mutations and expression in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1096344

Expression and function of TRK-B and BDNF in human neuroblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1096344

Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1096344

10.1517/13543784.2015.1096344

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26457764%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

1 reference